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Abstract
Background: Metastatic prostate cancer is associated with a high morbidity and mortality but the
spreading mechanisms are still poorly understood. The aminobisphosphonate alendronate, used to
reduce bone loss, has also been shown to inhibit the invasion and migration of prostate cancer cells
in vitro. We used a modified orthotopic PC-3 nude mouse tumor model of human prostate cancer
to study whether alendronate affects prostate tumor growth and metastasis.
Methods: PC-3 cells (5 × 105) were implanted in the prostates of nude mice and the mice were
treated with alendronate (0.5 mg/kg/day in PBS, s.c.) or vehicle for 4 weeks. After sacrifice, the sizes
of tumor-bearing prostates were measured and the tumors and prostate-draining regional iliac and
sacral lymph nodes were excised for studies on markers of proliferation, apoptosis, angiogenesis
and lymphangiogenesis, using histomorphometry and immunohistochemistry.
Results: Tumor occurrence in the prostate was 73% in the alendronate-treated group and 81% in
the control group. Mean tumor size (218 mm3, range: 96–485 mm3, n = 11) in the alendronate-
treated mice was 41% of that in the control mice (513 mm3, range: 209–1350 mm3, n = 13) (p <
0.05). In the iliac and sacral lymph nodes of alendronate-treated mice, the proportion of metastatic
area was only about 10% of that in control mice (p < 0.001). Immunohistochemical staining of
tumor sections showed that alendronate treatment caused a marked decrease in the number of
CD34-positive endothelial cells in tumors (p < 0.001) and an increase in that of ISEL positive
apoptotic cells in tumors as well as in lymph node metastases (p < 0.05) compared with those in
the vehicle-treated mice. The density of m-LYVE-1-stained lymphatic capillaries was not changed.
Conclusion: Our results demonstrate that alendronate treatment opposes growth of orthotopic
PC-3 tumors and decreases tumor metastasis to prostate-draining lymph nodes. This effect could
be at least partly explained by decreased angiogenesis and increased apoptosis. The results suggest
that bisphosphonates have anti-tumoral and anti-invasive effects on primary prostate cancer.
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Background
Every year prostate cancer is diagnosed in more than 500
000 men worldwide [1]. Approximately 30 – 50% of them
have evidence of metastatic disease, which results in a
high morbidity and mortality. In advanced prostate can-
cer, 25 – 42% of the patients have metastases in regional
lymph nodes [2] and about 70% have metastases in bone
[3]. The mechanisms behind invasive prostate cancer are
still largely unknown and the metastatic disease is basi-
cally incurable.
Only a few experimental models of spontaneous prostate
cancer exist, since this malignancy is uncommon in non-
human mammals. To study tumor growth in vivo, immu-
nodeficient mice are commonly used as models [4,5]. In
athymic nude mice, human prostate cancer cells can be
grown subcutaneously or tumor cells can be inoculated
orthotopically into the prostate [5]. In order to mimic a
metastatic disease, cancer cells can also be inoculated into
the circulation either via the tail vein [6] or the left cardiac
ventricle [7]. However, considering the structure and func-
tion of stroma, vasculature and lymphatic vessels ortho-
topic tumors provide the most relevant environment for
tumor growth and invasion.
Bisphosphonates are used in prevention and treatment of
metastatic and myelomatous bone disease [8-10] and
osteoporosis [11]. They primarily inhibit osteoclast-medi-
ated bone resorption but in addition to this, they have
been shown to have direct effects on different types of
tumor cells and tumors. Our previous results [12] showed
that the aminobisphosphonate alendronate is able to
strongly reduce invasion and migration of PC-3 prostate
cancer cells at low, non-toxic concentrations and in a
dose-dependent manner. Alendronate also inhibits PC-3
cell adhesion to extracellular matrix proteins in vitro
[13,14] and secretion of MMP:s by tumor cells [15]. Other
bisphosphonates (clodronate, pamidronate, ibandronate
and zoledronate) have been shown to induce apoptosis of
breast cancer cells in vitro [16,17], inhibit angiogenesis
[18] and, at high concentrations, to inhibit cell prolifera-
tion [19].
Interesting results have also been reported in animal mod-
els. They show that in models of bone metastasis of breast
cancer, bisphosphonates effectively reduce tumor burden
in bone [20,21], which has primarily been explained by
inhibition of osteoclast-mediated bone resorption and
decreased release of bone matrix-bound growth factors.
Besides these indirect effects on bone metastasis, bisphos-
phonates have been shown to decrease tumor spread and
formation of visceral metastases and increase survival in
tumor-bearing mice. Alendronate has been shown to
inhibit intraperitoneal dissemination of ovarian cancer
cells [22] and the newer aminobisphosphonates in partic-
ular, such as zoledronate and minodronate, have been
reported to inhibit growth in 4T1/luc breast tumors [23],
melanoma [24], cervical carcinoma [25] and mesotheli-
oma tumors [19], as well as to suppress lung metastasis in
osteosarcoma-bearing mice [26]. In addition, zoledronate
can inhibit angiogenesis in subcutaneous matrix implants
[27], in the prostates of testosterone-treated castrated rats
[18] and in a mouse model of cervical carcinogenesis [19].
In clinical trials, Kanis et al. [8] and Powles et al. [28]
showed that clodronate decreased the tumor burden of
breast cancer in bone. The overall survival of the patients
was better but there was no difference in visceral metas-
tases. In a study by Diel et al. [29], clodronate reduced
both bone and visceral metastases in breast cancer
patients, although Saarto et al. [30] have reported the con-
flicting results as regards visceral metastasis.
The aim of the present study was to examine the effect of
alendronate treatment on prostate tumor growth, inva-
sion and lymph node metastasis. For this purpose we
improved and exploited the model of orthotopic PC-3
prostate tumors in nude mice. The effects of the aminobi-
sphosphonate alendronate on prostate tumor growth and
spread to prostate-draining sacral and iliac lymph nodes
were investigated by measuring tumor size and analyzing
the tumors by means of histomorphometry and by carry-
ing out immunohistochemical staining of markers of pro-
liferation, angiogenesis, lymphangiogenesis and
apoptosis. Using this model we demonstrate that alendr-
onate decreases PC-3 prostate tumor growth and size of
metastases in prostate-draining iliac and sacral lymph
nodes in nude mice.
Methods
Animals
Eight-week-old male athymic nu/nu mice (Harlan Win-
kelman GmbH, Borchen, Germany) were maintained in a
pathogen-free environment, under controlled conditions
(20–21°C, 30–60% relative humidity and 12-hour light-
ing cycle). They were fed with small-animal food pellets
(RM3 ESQC, Special Diet Services, Witham, England) and
supplied with autoclaved tap water ad libitum. Animal
welfare was monitored daily, looking for clinical signs,
and the animals were weighed twice a week. The animal
experiments were carried out according to the European
Convention for the Protection of Vertebrate Animals used
for Experimental and other Scientific Purposes, and stat-
utes 1076/85 and 1360/90 of The Animal Protection Law
in Finland and EU Directive 86/609. The experimental
procedures were reviewed by the local Ethics Committee
on Animal Experimentation of the University of Turku
and approved by the local Provincial State Office of West-
ern Finland.BMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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Cell culture
The human prostate cancer cell line PC-3 was obtained
from the American Tissue Type Culture Collection (Rock-
ville, MD). At near confluence, the cells were harvested
and suspended at a concentration of 5 × 105/20 μl in a
sterile dye solution consisting of phosphate-buffered
saline (PBS; Biochrom AG, Berlin, Germany) with green
food color 33022 (0.5 g/ml; Roberts Oy, Turku, Finland).
The cells were kept on ice until used for inoculation. Cell
viability was 97% or above at the time of inoculation, as
determined by trypan blue staining of the cell suspension.
Orthotopic inoculation into the prostate
Half an hour before inoculation of tumor cells an analge-
sic drug (Temgesic, 0.3 μg/g, Schering-Plough Nv, Brus-
sels, Belgium) was injected subcutaneously. The mice
were anesthetized by means of isofluran inhalation
(1.5–3%, air flow 200 ml/min, Univentor 400 anesthesia
unit, Univentor Ltd., Zejtun, Malta) and placed in a
supine position under a sterile cover. An incision was
made 3 mm above the pubic symphysis and the bladder
and seminal vesicles were carefully lifted to expose the
dorsal prostate. To improve visual control of correct inoc-
ulation into the prostate, the cell suspension was supple-
mented with nontoxic green food color. Then, 5 × 105
cells with the dye, were slowly inoculated into the ventral
prostate through the dorsal prostate at a 45° angle, avoid-
ing the urethra. The success of inoculation could be veri-
fied by means of the green color. If leakage into the
peritoneal cavity or urethra/bladder was observed, the
mice were not included in the experiment. Inoculation
was performed with a 30 G needle attached to a 25 μl glass
syringe (both Hamilton Bonaduz AG, Bonaduz, Switzer-
land). After inoculation, the abdominal muscle layer was
closed with a 4-0 absorbable suture (Bondek plus, polyg-
lycolic acid-coated suture, Genzyme GmbH, Neu-Isen-
berg, Germany) and the skin with a 4-0 nonabsorbable
suture (monofilament, polyamide suture, Genzyme
GmbH, Neu-Isenberg, Germany).
Tumor growth and metastasis to local lymph nodes
In order to study the effects of alendronate on prostate
tumor growth and invasion, mice were randomized
according to weight into 2 groups. The orthotopic experi-
ments were performed using the total numbers of 15 and
16/group considered to be large enough for the analyses
of the statistical significance of the results. Mice in the
alendronate group were daily treated with alendronate
(0.05 mg/kg s.c., provided by Merck&Co., Inc., White-
house Station, NJ) in 100 μl PBS and mice in the control
group were injected daily with 100 μl PBS. Alendronate
and control treatments were started on the day of ortho-
topic inoculation of 5 × 105 PC-3 cells. The mice were sac-
rificed 4 weeks after inoculation. Prostate (including
tumor) size was measured with calipers and the volume
calculated according to the method described by Janik et
al. [31] as length × width × depth × π/6. The prostate
lobes, selected internal organs (lungs, kidneys, adrenal
glands, liver and spleen), regional lymph nodes (iliac and
sacral), distant lymph nodes (inguinal, sciatic, axillary
and brachial), hind limbs and vertebrae were macroscop-
ically examined for the occurrence of tumors, excised and
immersed in 4% neutral-buffered formalin. The hind
limbs and vertebrae were radiographed and the bone sam-
ples were decalcified in 10% EDTA solution for two weeks
before further processing.
Histology and immunohistochemistry
Formalin-fixed tissue samples were embedded in paraffin
and 5-μm sections were cut and stained with hematoxylin
and eosin (H&E) using standard techniques. The relative
areas of necrosis in tumors and the relative area of tumor
metastases in iliac and sacral lymph nodes was deter-
mined from H&E-stained sections using an analysis pro-
gram for histomorphometry (AxioVision software, Carl
Zeiss Microimaging GmbH, Oberkochen, Germany). The
lymph nodes were cut through and 8 to 10 sections/
lymph node were analyzed in order to determine meta-
static area and the results were expressed as percentage of
the total area of the lymph node.
The tumor sections were treated with antibodies: mouse
monoclonal anti-LYVE-1 (a gift from Dr. David Jackson)
[32], rat monoclonal anti-CD34 (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA) or mouse monoclonal anti-Ki-
67 (Novocastra Laboratories Ltd., Newcastle upon Tyne,
UK) o/n at +4°C. The samples were then treated with
biotin-labeled goat anti-mouse secondary antibodies
(Vector Laboratories, Burlingame, USA), biotin-labeled
rabbit anti-rat secondary antibodies (DAKO Denmark A/
S, Glostrup, Denmark), or biotin-labeled rabbit anti-
mouse secondary antibodies [33], respectively. A mouse-
on-mouse kit (Vector Laboratories, Burlingame, CA) was
used with Ki-67 antibody staining to inhibit non-specific
staining of anti-mouse secondary antibody. The in situ
end labeling (ISEL) method was used to detect apoptotic
cells. Negative controls (sections of every sample stained
without the primary antibody) were used to verify the spe-
cificity of staining. The relative numbers of Ki-67- and
ISEL-positive cells were counted by means of a 10 × 10
grid using three sections at 500 μm intervals to make sure
that the same cell was not counted twice. Altogether 3.000
cells/tumor from 3 different levels were counted. The
length of the CD34-positive vessels was counted from the
3 most vascularized fields of each tumor by drawing lines
following stained vessels and measuring the length of the
lines using AxioVision software (Carl Zeiss Microimaging
GmbH, Oberkochen, Germany). The sections of prostate-
draining lymph nodes were studied for Ki-67, CD34 and
ISEL immunostaining using the same method asBMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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described above. The results were blind-tested by three
independent analyzers.
RNA isolation and Northern blot analysis
Total RNA was extracted from PC-3 cells using the gua-
nidinium isothiocyanate method Chomczynski and Sac-
chi [34]. Subsequently, 20 μg of RNA was separated by
electrophoresis, stained with ethidium bromide and blot-
ted on a GeneScreen Plus nylon membrane (NEN
Research Products, Boston, MA), using standard condi-
tions suggested by the manufacturer. A cDNA insert
(kindly provided by Professor Kari Alitalo, University of
Helsinki, Finland) [35] of human VEGF-C was [32P]-
dCTP-labeled by the random priming method (Ready-to-
go DNA labeling Beads, Pharmacia Biotech, Piscataway,
NJ). Hybridization and exposure to X-ray film were car-
ried out using conditions suggested by the manufacturer.
Western blot analysis
Serum-free DMEM conditioned by PC-3 cells for 2 days
was harvested from the cultures. The conditioned
medium was centrifuged to remove cell debris. Heparin-
binding proteins were isolated from the supernatant with
100 μl of heparin-sepharose (1:1 slurry, Amersham Phar-
macia Biotech., Piscataway, NJ) overnight at +4°C.
Heparin-sepharose beads were sedimented by centrifuga-
tion and washed three times with 20 mM Tris-HCl, pH
7.4, 300 mM NaCl. Heparin-sepharose-bound proteins
were extracted by means of 5-min incubation in Laemmli
sample buffer at +95°C and separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Medium conditioned by 3 × 106 cells was used per well.
After transfer to nitrocellulose membranes (Bio-Rad),
VEGF-C was detected using a 1:500 dilution of a goat pol-
yclonal antihuman VEGF-C antibody (Santa Cruz Bio-
technology, USA) and a secondary antibody, horseradish
peroxidase-labeled anti-goat IgG (DAKO, Denmark),
which was used at 1:2000 dilution. Protein bands were
visualized using the ECL chemiluminescence detection
system (Amersham Corp.). Conditioned media from
human breast cancer cells (MCF-7 cells; 1 × 106/well), sta-
bly transfected with VEGF-C, were used as positive con-
trols and normal goat IgG (R&B-Systems Inc.,
Minneapolis, MN) was used instead of anti-VEGF-C anti-
body as a negative control.
Statistics
Results were expressed as mean value ± SD. Statistical sig-
nificance was taken to be p < 0.05, using two-tailed Stu-
dent's t-test.
Results
Effects of alendronate on tumor size and lymph node 
metastasis of orthotopic PC-3 prostate tumors
Our earlier experiments indicated that PC-3 prostate can-
cer cells inoculated orthotopically to nude mouse ventral
prostate (Fig 1A) form tumors (Fig 1B) and develop
lymph node metastases (Figure 1C, D, E) in a time-
dependent manner (data not shown). Our refinement of
the inoculation method – adding dye to the cell suspen-
sion – strengthens the applicability of orthotopic PC-3
tumors and provides a model for studying prostate cancer
growth and spread. In successful inoculation no leakage
to the peritoneal cavity was observed. The color was first
seen in the ventral prostate, from where it spread to the
dorsolateral lobes. Spreading of dye was fast, probably
partly in a retrograde manner via prostatic ducts and pos-
sibly because mouse prostatic lobes are not separated by a
capsule, but only by a thin, delicate layer of fibromuscular
stroma [4]. Tumors formed in both the ventral and dorso-
lateral lobes of the prostate (Figure 1B). In the dorsola-
teral lobes, the gene expression signature is most like that
in the peripheral zone of the human prostate [36].
To study the effect of alendronate on tumor growth and
spread, nude mice were inoculated orthotopically with 5
× 105 cells into the ventral prostate and the animals were
treated daily either with a subcutaneous injection of alen-
dronate (0.5 mg/kg/day in PBS) (n = 15) or PBS (control,
n = 16) for 4 weeks. The dose of alendronate given to the
mice was that to be equal to the standard clinical dose.
Tumor growth in the prostate was observed in most of the
nude mice inoculated with PC-3 cells. The end point of 4
weeks was selected on the basis of previous time course
studies (not shown) to ensure that the orthotopic tumors
would not grow too big.
Tumors grown in the prostates of nude mice showed a
solid and homogeneous morphology in H&E staining
(Figure 1A: sham-operated mouse, 1B: mouse inoculated
with PC-3 cells). Four weeks after inoculation of PC-3
cells, the tumors were mostly confined to the ventral pros-
tate, in which only a few glandular structures were left, but
often tumor cells had spread to all lobes of the prostate
gland. Tissue samples that were classified as tumor-nega-
tive were re-sectioned and sections from several levels of
tissue were stained and analyzed. If samples were classi-
fied as tumor-negative twice by three independent analyz-
ers they were considered as being so. Metastasis in
prostate-draining lymph nodes was first observed as
growth of tumor cells in the sub-capsular area, which later
extended to the cortex and medulla. In some mice, the
lymph nodes were totally occupied by metastasized tumor
(Figure 1 lymph nodes of sham-operated (C) and ortho-
topic PC-3 tumor bearing mice, D, E).BMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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Based on macroscopic and histological analysis, tumor
occurrence was 73% at 4 weeks in the alendronate-treated
group and 81% in the PBS-treated group (Table 1). At this
4-week time point metastases were found in 64% of
regional iliac and sacral lymph nodes in the group that
received alendronate. In the mice treated with PBS, metas-
tasis in iliac and sacral nodes was found in 54% of the ani-
mals. The difference between the groups was not
statistically significant (Table 1). The treatments did not
affect the body weight of the animals (data not shown).
The volume of the tumor-bearing prostate at 4 weeks was
significantly greater in the control group than in the alen-
dronate-treated group (mean of 513 ± 341 mm3 [range
209–1350 mm3]  vs. mean of 218 ± 123 mm3 [range
96–485 mm3], respectively, p < 0.05, Figure 2A). Histo-
morphometric analysis of the lymph nodes also demon-
strated that there were marked differences in metastatic
invasion of the lymph nodes in alendronate-treated mice
compared with control mice. Quantification of the rela-
tive areas of metastases showed that the proportion of
tumor area in iliac and sacral lymph nodes was signifi-
cantly smaller in the alendronate group than in the con-
trol group (Figure 2B; 2% [ALN] vs. 26% [PBS] p < 0.001).
However, no statistically significant difference was
observed in the total size of lymph nodes between treat-
Morphology of orthotopic PC-3 prostate tumors and metastases in prostate draining lymph nodes Figure 1
Morphology of orthotopic PC-3 prostate tumors and metastases in prostate draining lymph nodes. Prostate 
from sham-operated control mice (A) and tumor bearing mice (B) 4 weeks after inoculation of PC-3 cells (tumor tissue, 
arrows). DD = ductus deferens, DP = dorsal prostate, SV = seminal vesicle, T = tumor tissue, U = urethra, VP = ventral pros-
tate (Bar = 500 μm). Prostate draining lymph nodes of sham-operated control mice (C) and from prostate tumor bearing mice 
(D and E). Infiltrating tumor cells were first observed in the sub-capsular areas of lymph nodes (arrows, D) and in advantaged 
cases cortex and medulla (arrows, E). Cap = lymph node capsule, (Bar = 500 μm).
Table 1: Occurrence of tumor growth in prostate and lymph node metastasis of in nude mice treated with alendronate (ALN) or saline 
(PBS)
Treatment Occurrence of tumor growth in prostate (%) Occurrence of metastasis in prostate draining lymph nodes (%)
ALN 11/15 (73) 7/11 (64)
PBS 13/16 (81) 7/13 (54)
Tumors were produced by orthotopic inoculation of 5 × 105 PC-3 cells and tumors were allowed to grow for 4 weeks.BMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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ment groups or between non-metastatic and metastatic
lymph nodes at 4 weeks after inoculation of tumor cells.
This is possibly caused by several other factors than metas-
tasis that can influence the size and activity of lymph node
tissue. This may partly cover the changes caused by metas-
tases. Hence, in addition to macroscopic examination his-
tological examination is always needed in detection of
metastasis in lymph nodes.
Effects of alendronate on morphology and on markers of 
angiogenesis, proliferation and apoptosis in PC-3 prostate 
tumors and prostate-draining lymph nodes
No changes in morphology were observed in histological
(H&E) staining of the prostate tumors in the alendronate
and control groups (Figure 3A, B). To assess the character-
istics of the tumors in more detail, immunohistochemical
staining was performed. The proliferation rate was deter-
mined by immunohistochemical staining for Ki-67. No
differences were seen between the alendronate group and
the control group (Figure 3C–E). The relative number of
apoptotic cells was determined by using ISEL staining.
Apoptosis was increased by 40% in alendronate-treated
tumors in comparison with control tumors (p < 0.05, Fig-
ure 3F–H). The size of necrotic areas was also increased,
but the difference was not statistically significant (data not
shown). The prostate draining lymph nodes were also
studied by means of immunohistochemistry. Our results
demonstrate, that apoptosis was increased by 30% in met-
astatic tissue of iliac and sacral lymph nodes in alendro-
nate-treated mice compared with vehicle-treated mice (p <
0.05, Figure 3L–N). No statistically significant differences
were detected in proliferation in metastatic tissue (data
not shown). The blood capillaries of orthotopic PC-3
tumors were identified using CD34 antibodies specific for
endothelial cells. Capillary density was significantly lower
in the alendronate-treated group than in the control
group (p < 0.001, Figure 3L–N). No statistically significant
differences were found, when vascularization of lymph
node metastases was studied. On the other hand, the
small sizes of the metastatic areas in alendronate-treated
lymph nodes made reliable estimation of CD34 staining
difficult (data not shown).
Alendronate treatment has no effect on 
lymphangiogenesis in PC-3 prostate tumors
Because alendronate treatment strongly decreased the
metastatic area in lymph nodes of PC-3 tumor-bearing
mice, we studied the effect of the treatment on the density
of lymphatic vessels in tumors. The PC-3 cells were found
to produce the lymphangiogenic growth factor VEGF-C, as
determined by Northern (Figure 4A) and Western blotting
(Figure 4B). This is in accordance with previous results
[37,38]. Immunostaining of orthotopic tumors with a
mouse-LYVE-1 antibody specific for lymphatic endothe-
lium showed a rich network of lymphatic vessels. In the
tumors grown for 4 weeks, staining was mainly observed
in the peripheral area of the tumors and in the peritu-
moral area (Figure 4C [ALN] and 3D [PBS]). In many
Effect of alendronate treatment on the size and lymph node metastasis of orthotopic PC3 prostate tumors Figure 2
Effect of alendronate treatment on the size and lymph node metastasis of orthotopic PC3 prostate tumors. 
Tumor size was measured using the formula: length × width × depth × π/6. The tumor volume was significantly smaller in alen-
dronate treated mice compared with the control mice (A), p < 0.05, Student's t-test. According to the histomorphometrical 
analysis (B), the relative area of lymph node metastasis (%) was significantly smaller in alendronate-treated (n = 7) than in PBS-
treated control animals (n = 7), p < 0.001, Student's t-test].BMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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tumors, tumor cell growth was also observed inside lym-
phatic capillaries in all treatment groups (Figure 4E,
arrows). Alendronate treatment did not, however, result
in any differences in the density of mouse-LYVE-1-stained
lymphatic capillaries in comparison with vehicle-treated
mice (Figure 4F).
Histological examination of internal organs, long bones 
and vertebrae for metastases
Only one mouse in the control group had metastatic
growth in the lungs. No metastases were found in the
liver, spleen or parenchyma of the kidneys or adrenal
glands within the time period of the experiment. No bone
metastases were found in X-ray analysis or histology of
Effects of alendronate treatment on morphology and on immunohistochemical staining of markers of proliferation (Ki-67),  apoptosis (ISEL) and angiogenesis (CD34) in orthotopic PC-3 prostate tumors and lymph nodes Figure 3
Effects of alendronate treatment on morphology and on immunohistochemical staining of markers of prolifer-
ation (Ki-67), apoptosis (ISEL) and angiogenesis (CD34) in orthotopic PC-3 prostate tumors and lymph nodes. 
Alendronate treatment increased apoptosis in tumors and prostate draining lymph nodes and decreased angiogenesis in 
tumors (Bar = 100 μm). * Significantly different from PBS-treated control, p < 0.05, *** significantly different from PBS-treated 
control, p < 0.001, NS nonsignificant (Student's t-test).BMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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vertebrae, tibiae or femora of mice in any treatment
group. The 4-week observation period was probably too
short a time to obtain distant metastases using parental
PC-3 cells. Our earlier experiments showed that distant
metastases in nude mice can be obtained using an intrac-
ardiac inoculation method (data not shown) where suffi-
cient tumor cells can be inoculated into the blood stream.
Discussion
In prostate cancer, 25–42% of patients have metastases in
regional lymph nodes at the time of diagnosis [2,39]. Our
modified orthotopic PC-3 tumor model, which invades to
lymph nodes [5], enables studies on this stage of prostate
cancer metastasis. On the other hand, prostate cancer
patients often have bone metastases and they are treated
with bisphosphonates. Alendronate and other bisphos-
phonates have been reported to decrease the spread of var-
Network and density of lymphatic vessels in PC-3 prostate tumors from alendronate-treated and PBS-treated mice Figure 4
Network and density of lymphatic vessels in PC-3 prostate tumors from alendronate-treated and PBS-treated 
mice. PC-3 cells were analyzed by Northern and Western blots for expression of VEGF-C (A, B, respectively, from left to 
right: culture media from PC-3 cells, positive control [culture media from MCF-7 cells stably transfected with VEGF-C; n = 1 × 
106 cells], negative control [normal goat IgG]). Sections from PC-3 prostate tumors were immunostained for lymphatic 
endothelial cells using m-LYVE-1 antibodies (C, D, E). Positive staining was observed primarily in the tumor periphery and in 
the peritumoral area. Tumor cells were observed also inside lymphatic vessels (E, arrows). Densities of LYVE-1-positive vessels 
were analyzed from the 3 best vascularized fields/tumor n (ALN) = 11, n (PBS) = 13. No statistically significant difference was 
detected between alendronate-treated and control tumors (F, p = 0.67, Student's t-test). (Bar = 100 μm).BMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
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ious other tumors in vivo. Our own experiments have also
previously shown alendronate inhibition of prostate can-
cer cell invasion in vitro. This prompted us to study the in
vivo growth and invasion of orthotopic prostate tumors
modeling primary prostate cancer.
Alendronate is an aminobisphosphonate that is princi-
pally used in treatment of osteoporosis. Detailed molecu-
lar mechanisms have not been studied until recently.
Alendronate has been shown to have inhibitory effects on
osteoclast generation and maturation as well as on osteo-
clast activity [40]. Although bone metastases of prostate
cancer are usually more osteosclerotic than osteolytic,
there are indications that bisphosphonates relieve bone
pain and inhibit fractures in prostate cancer patients [41-
44]. Bisphosphonates thus seem to be beneficial in treat-
ment of prostate cancer bone metastases, at least in sub-
groups with severe bone pain [44]. In experimental
models bisphosphonates have been shown to inhibit
tumor invasion when used as a combination therapy with
chemotherapeutics (taxol) [45].
Our present results demonstrate that alendronate is able
to inhibit prostate tumor growth and invasion to local
lymph nodes in vivo in nude mice. Surprisingly, a major
effect of alendronate, besides being associated with a
decreased size of lymph node metastases, was a decrease
of tumor size. To our knowledge, alendronate has not ear-
lier been reported to inhibit the growth of primary pros-
tate cancer in vivo. Alendronate treatment did not,
however, decrease the rate of proliferation as shown by Ki-
67 immunohistochemical staining of alendronate vs. con-
trol-treated prostate tumors. This is in line with the results
of our previous studies in vitro, in which alendronate did
not affect the proliferation of PC-3 cells over a wide range
of concentrations that strongly inhibited invasion [12].
Other studies have, however, revealed a decreased rate of
proliferation in vitro in the presence of alendronate but in
those studies very high (micromolar) concentrations of
alendronate were used [19,46,47].
In our in vivo study alendronate treatment did, however,
increase apoptosis in prostate tumors, which could con-
tribute to decreased tumor growth. This is in agreement
with the results of some other studies in which in vitro cul-
tures [16,17] and in vivo tumor models [48] have been
used. Relatively high concentrations of bisphosphonates
have usually been needed to trigger apoptosis in vitro but
in vivo bisphosphonate treatments with doses and sched-
ules comparable to those used in clinical treatments have
been reported to induce apoptosis in several models as
regards both bone [20] and visceral metastases [19,22-
26]. This suggests that besides direct cellular effects, other
mechanisms may also contribute to decreased cell survival
in vivo.
Another effect that may contribute to decreased tumor
size and tumor cell survival in alendronate-treated mice is
inhibition of angiogenesis, as suggested by a decreased
density of CD34-positive blood vessel capillaries. This
observation is also in accordance with earlier reports on
the capacity of various bisphosphonates to inhibit angio-
genesis in vitro and in vivo in the context of some physio-
logical and pathological conditions. The decreased
angiogenesis associated with bisphosphonate treatment
has been related to modulation of endothelial cell prolif-
eration, adhesion, migration [49] and apoptosis [19].
Zoledronate as well as alendronate has been found to
inhibit secretion and activity of MMP-2 and MMP-9 by
tumor cells and tumor-infiltrating macrophages in mouse
models of cervical cancer [19] and prostate cancer [50]. In
addition, both minodronate and zoledronate affect VEGF
interaction with VEGF receptors and signaling in endothe-
lial cells [19,23]. In our prostate tumors alendronate facil-
itated apoptosis and inhibited angiogenesis, the latter
leading to restricted nutrition and oxygenation, thereby
affecting tumor growth. There was, however, no statisti-
cally significant increase in the proportion of necrotic
areas in alendronate-treated tumors (data not shown).
Orthotopic PC-3 tumors metastasize to sacral and iliac
lymph nodes that drain the prostate [5]. Immunostaining
for LYVE-1 demonstrated a dense network of lymphatic
capillaries in the periphery of tumors as well as in the per-
itumoral area in our PC-3 prostate tumors. A high level of
expression of lymphangiogenic VEGF-C has been shown
to correlate with the density of lymphatic capillaries
[49,51-53] and increased lymphangiogenesis has been
shown to facilitate tumor metastasis to lymph nodes [51-
55] although conflicting results have also been published
[56]. Our previous studies with orthotopic mammary
tumors in nude mice, and those of others, have demon-
strated that VEGF-C stimulates lymphangiogenic tumor
spread in vivo [54,55]. High expression level of VEGF-C
has been detected in about 50% of human cancers [49].
PC-3 cells and tumors express VEGF-C at a high level
[35,37,38], and it is thus conceivable that the spread of
orthotopic PC-3 tumors to lymph nodes occurs primarily
via lymphatic vessels. Demonstration of tumor growth
inside lymphatic capillaries in our orthotopic tumors also
speaks for a lymphatic route of metastasis. Treatment with
alendronate reduced the metastatic area in lymph nodes
but it did not, however, affect the density of the lymphatic
vessel network or the number of lymph node metastases.
Therefore, it is possible that the decreased metastatic
growth in lymph nodes is explained by alendronate regu-
lation of tumor growth via effects on tumor cells them-
selves or on angiogenesis, rather than via effects on
lymphangiogenesis [18,49]. According to our results
increased apoptosis of tumor cells and/or endothelial
cells in both primary tumors and lymph node metastasesBMC Cancer 2008, 8:81 http://www.biomedcentral.com/1471-2407/8/81
Page 10 of 12
(page number not for citation purposes)
could be a major mechanism by which alendronate
decreased metastatic area in iliac and sacral lymph nodes.
Our previous results demonstrated a strong inhibitory
effect of alendronate on PC-3 cell invasion in vitro [12]
and other investigations have shown inhibition of MMP
secretion and associated invasion capacity of prostate can-
cer cells [15]. These results are in line with the decreased
cell invasion to and limited growth of PC-3 tumors in
local lymph nodes of alendronate-treated mice. Decreased
angiogenesis is also associated with decreased metastatic
potential [57] and could as such contribute to the
decreased metastatic growth in lymph nodes.
Our results were based on analyses at an end-point of 4
weeks, which limits the estimation of alendronate effects
on tumor formation and progression to this time point.
Future experiments with noninvasive imaging methods
will allow following growth and spreading of orthotopic
tumors at several intervening time points over an optimal
time period without markedly expanding the numbers of
experimental animals.
There is evidence that the inhibitory effects of aminobi-
sphosphonates are largely mediated via the mevalonate
pathway [12,13,40]. Although the precise mode of action
of aminobisphosphonates is not understood, the mecha-
nisms that have been recognized are based on their ability
to impair post-translational prenylation of Ras, Rac and
Rho [12,58]. Aminobisphosphonates have been found to
target farnesylpyrophosphate and/or geranylgeranylpyro-
phosphate synthetase, which leads to decreased genera-
tion of farnesyl diphosphate and geranylgeranyl
diphosphate. These intermediates are needed for post-
translational prenylation of small GTP-binding proteins
(Ras, Rac and Rho) which are essential for many cellular
functions such as proliferation, survival and invasiveness.
It is probable that interference with prenylation reactions
is involved in many effects of aminobisphosphonates
such as decreased angiogenesis and cell migration as well
as increased apoptosis [58].
Recent reports have also shown evidence that aminobi-
sphosphonates can induce apoptosis and/or cause growth
arrest to G2/M phase in the same way than pyrophosphate
resembling bisphosphonates by production of an endog-
enous ATP analog [59]. Especially newer aminobisphos-
phonates can directly inhibit proliferation [19,60].
However, these growth inhibitory effects can be overcome
with excess geranylgeranyl pyrophosphate, which links
this mechanism to the bisphosphonate inhibition of the
mevalonate pathway.
Both aminobisphosphonates and pyrophosphate resem-
bling bisphosphonates have also shown to increase resist-
ance to the apoptotic and growth inhibitory effects in
some cancer cells. These effects are associated with activa-
tion of p38 mitogen activated protein kinase pathway and
may support cell survival and promote proliferation.
Interestingly, the p38-mediated effects may not be
dependent on the inhibition of the mevalonate pathway
[61]. It is possible that the p38-mediated survival effects
balance the growth inhibitory effects in the tumor models
as ours in which alendronate does not inhibit cell prolif-
eration.
Bisphosphonates bind to calcified bone matrix and accu-
mulate in bone very rapidly, which keeps blood levels of
the drug low in vivo. Studies carried out by Fournier et al.
[18] have revealed, however, that in rats at least, some
bisphosphonates including clodronate, zoledronate and
ibandronate, transiently accumulate in the prostate rather
than in several other non-calcified tissues before being
trapped by bone. Prostatic levels of bisphosphonates
reached a peak at 30–60 minutes after administration of
the drug and then declined. The mechanism of bisphos-
phonate accumulation in tumors is not understood. The
results of some studies have suggested that tumor calcifi-
cation, necrosis or activated macrophages have a role in
the uptake process [58,61-64]. Preferential prostatic accu-
mulation may partly explain the anticancer effects of alen-
dronate on prostatic tumors, and increase the possibilities
of exploiting bisphosphonates in the development of
therapies against prostate cancer.
Conclusion
The orthotopic PC-3 tumor model mimics the growth of
primary prostate cancer and its invasion to lymph nodes.
Our study demonstrates that alendronate inhibits ortho-
topic prostate tumor growth and decreases the size of
metastases in lymph nodes in vivo in nude mice. Alendro-
nate treatment was associated with strongly inhibited ang-
iogenesis and increased apoptosis, which may largely
explain decreased tumor growth. Reduced PC-3 prostate
tumor growth together with the previously observed inhi-
bition of PC-3 cell invasion/migration may thus markedly
contribute to decreased lymph node metastasis in alendr-
onate-treated mice. The results suggest that besides
decreasing metastasis, bisphosphonates can inhibit pri-
mary tumor growth in prostate cancer.
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